Alexandra Snyder Charen

List of Publications by Year
in descending order

44 papers	22,964 citations	172207 29 h-index	288905 40 g-index
52 all docs	52 docs citations	52 times ranked	30208 citing authors

#	Article	IF	Citations
1	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756
2	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2189-2199.	13.9	3,753
3	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
4	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
5	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
6	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
7	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
8	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 843-852.e4.	7.7	827
9	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	13.7	697
10	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	15.2	604
11	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
12	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell, 2017, 170, 927-938.e20.	13.5	368
13	Acquired resistance to immunotherapy and future challenges. Nature Reviews Cancer, 2016, 16, 121-126.	12.8	353
14	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
15	Cancer Neoantigens and Applications for Immunotherapy. Clinical Cancer Research, 2016, 22, 807-812.	3.2	188
16	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2015, 373, 1984-1984.	13.9	166
17	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
18	Unraveling tumorâ€“immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics, 2020, 52, 582-593.	9.4	136

#	Article	IF	Citations
19	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer Immunology Research, 2017, 5, 84-91.	1.6	126
20	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
21	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	3.2	100
22	A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. European Radiology, 2017, 27, 3991-4001.	2.3	92
23	Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell Reports, 2018, 23, 512-521.	2.9	90
24	Genetic Basis for Clinical Response to CTLA-4 Blockade. New England Journal of Medicine, 2015, 372, 783-783.	13.9	85
25	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. , 2022, 10, e003091.		67
26	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
27	Immunogenic peptide discovery in cancer genomes. Current Opinion in Genetics and Development, 2015, 30, 7-16.	1.5	63
28	Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. , 2020, 8, e001126.		54
29	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications, 2022, 13, 1935.	5.8	37
30	Could microbial therapy boost cancer immunotherapy?. Science, 2015, 350, 1031-1032.	6.0	36
31	Use of Circulating Tumor DNA for Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 6909-6915.	3.2	34
32	Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer. BMC Cancer, 2018, 18, 87.	1.1	33
33	Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology, 2019, 152, 251-258.	0.6	33
34	Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Immunity, 2017, 47, 221-223.	6.6	31
35	Current strategies for intratumoural immunotherapy â€“ Beyond immune checkpoint inhibition. European Journal of Cancer, 2021, 157, 493-510.	1.3	28
36	Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma. Cancers, 2020, 12, 3403.	1.7	24

#	Article	IF	Citations
37	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. Immunity, 2022, 55, 56-64.e4.	6.6	19
38	Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. Cancer Discovery, 2016, 6, 1210-1211.	7.7	14
39	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. PLoS ONE, 2018, 13, e0208422.	1.1	14
40	Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where Is the Future?. Seminars in Oncology, 2013, 40, 347-360.	0.8	13
41	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer. Gynecologic Oncology Reports, 2022, 39, 100926.	0.3	10
42	Genetics and immunology: reinvigorated. OncoImmunology, 2015, 4, e1029705.	2.1	7
43	Liver-directed conversion therapy in metastatic colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 322-8.	0.6	1
44	Immunogenomics. , 2019, , 99-110.		0